A Phase 1/2 interventional study of LTP and Placebo in Healthy Volunteers, Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Recruiting at 87 sites in 18 countries. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one has the largest planned enrollment, is the only one that started in 2024, is the only one in phase 1/2, and was the 12th registered.
699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries.
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 232 is above the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.
Part A Inclusion Criteria:
Part A Exclusion Criteria:
Part B Inclusion Criteria:
-Confirmed diagnosis of PAH, pre-randomization PVR ≥400 dyn.sec.cm-5, treatment with stable doses of standard-of-care PAH therapies, 6-minute walk distance ≥ 150 m and ≤450 m.
Part B Exclusion Criteria:
Any surgical or medical condition which may place the participant at higher risk from his/her participation in the study Women of child-bearing potential unless they are using highly effective methods of Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 24 hours after stopping study treatment.
History of to any of the study treatments or
Other protocol-defined inclusion / exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LTP
Drug: LTP
Drug: LTP
matching placebo
Drug: Placebo
LTP001
Placebo
Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations and adverse events up to and including the end-of-study visit.
Time frame: Baseline to Day 35
Part B-Treatment Period 1: Change in pulmonary vascular resistance (PVR)
PVR is a hemodynamic variable of pulmonary circulation and is measured by right heart catheterization.
Time frame: Baseline to Week 24
Part B-Treatment Period 2: Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)
Safety endpoints, including vital signs, ECG, clinical laboratory evaluations, treatment-emergent adverse events and discontinuations due to adverse events.
Time frame: From Day 1 until Week 106
Part A- Maximum observed plasma concentrations (Cmax)
Cmax is defined as the maximum (peak) observed concentration following a dose.
Time frame: Baseline to Day 35
Part A- Time to reach maximum plasma concentration (Tmax)
Tmax is defined as the time to reach maximum (peak) concentration following a dose.
Time frame: Baseline to Day 35
Part A- Area under plasma concentration-time curve from time zero to the last measurable concentration sampling time (AUClast)
AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast).
Time frame: Baseline to Day 35
Part A- Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-inf])
The AUC is the area under the plasma concentration from time zero to infinity (mass x time x volume-1).
Time frame: Baseline to Day 35
Part A- Terminal elimination half-life (T1/2)
T1/2 is the elimination half-life associated with the terminal slope.
Time frame: Baseline to Day 35
Part B-Treatment Period 1: Change in the Six-minute Walk Test (6MWT)
The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor.
Time frame: Baseline to Week 24
Part B-Treatment Period 1: Change in N-terminal pro-brain natriuretic peptide (NT-proBNP)
N-terminal pro brain natriuretic peptide (NTproBNP) are peptide (small proteins) that are either hormones or part of the peptide that contained the hormone at one time. They are continually produced in small quantities in the heart and released in larger quantities when the heart senses that it needs to work harder, as in heart failure.
Time frame: Baseline to Week 24
Part B-Treatment Period 1: Change in World Health Organization (WHO) functional class (FC)
The Investigator or study staff will assign a WHO functional class to a participant based on reports of symptoms and activity limitation. * Class I: symptom-free when physically active or resting. * Class II: no symptoms at rest, but normal activities such as climbing the stairs, grocery shopping, or making the bed cause some discomfort and shortness of breath. * Class III: resting may be symptom-free, but normal chores around the house are greatly limited due to shortness of breath and feeling tired. * Class IV: symptoms at rest and severe symptoms with an activity
Time frame: Baseline to Week 24
Part B-Treatment Period 2: Change in the Six-minute Walk Test (6MWT)
The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor.
Time frame: Baseline to Month 18
Part B-Treatment Period 2: Change in World Health Organization (WHO) functional class (FC)
The Investigator or study staff will assign a WHO functional class to a participant based on reports of symptoms and activity limitation. * Class I: symptom-free when physically active or resting. * Class II: no symptoms at rest, but normal activities such as climbing the stairs, grocery shopping, or making the bed cause some discomfort and shortness of breath. * Class III: resting may be symptom-free, but normal chores around the house are greatly limited due to shortness of breath and feeling tired. * Class IV: symptoms at rest and severe symptoms with an activity
Time frame: Baseline to Month 18
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Nov 2028, 49 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →